Taxotere docetaxel regulatory update

FDA granted priority review designation to AVE's sNDA for Taxotere to treat early-stage operable breast cancer with involved axillary lymph nodes. The PDUFA date is Sept. 17. Taxotere is marketed to treat patients with advanced or metastatic breast cancer after failure of prior chemotherapy, and patients with advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin. ...